Description: Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
Home Page: www.mycenax.com.tw
No. 66, Shengyi 2nd Road
Zhubei,
302041
Taiwan
Phone:
886 37 586 988
Officers
| Name | Title |
|---|---|
| Michael Hwang | Chief Exec. Officer |
| Jiong Xiang Chen | Mang. of Fin. and Accounting Department |
| Jin Lian Chen | Head of Audit |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2138 |
| Price-to-Sales TTM: | 7.9263 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 334 |